Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of PF-06409577 in Healthy Adults
NCT02286882Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Nov 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06409577 in diabetic nephropathy (DN), sponsored by Pfizer. Primary endpoints: Number of Participants With Adverse Events (AEs), Number of Participants With Laboratory Test Values of Potential Clinical Importance and 3 more. Started Nov 2014; status: terminated.
02
Drugs
PF-06409577
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT02286882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02286882.